News | January 16, 2025
Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby
Morepen Laboratories approves hiving off of medical devices business
Morepen Laboratories approves hiving off of medical devices business
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
There was no casualty or loss of human life in the incidence
The initiative will encourage and motivate emerging biotech startups, innovators and entrepreneurs
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Subscribe To Our Newsletter & Stay Updated
